Entellus Medical Secures $30 Million Financing To Expand Commercialization of Novel Treatments for Sinusitis
Summary
MINNEAPOLIS--(BUSINESS WIRE)--Entellus Medical, the Minnesota-based developer of novel, less invasive treatments for chronic conditions of sinusitis, has completed its Series D financing totaling $30MM. Ressemann said the latest round of funding will be used to expand their sales and customer support teams, and accelerate efforts to allow patients to be treated in an office-based setting. “We believe FinESS is an important new medical device therapy that combines the opportunity to deliver immediate relief with lasting results for the patient, while reducing overall health care expenditures. We look forward to working with the excellent management team of Entellus Medical to realize the full potential of the company.” Guido Neels will join the board of directors of the company, effective immediately. Founded in 2006, Entellus Medical is focused on providing unique solutions to address the unmet needs of ENT (ear, nose, and throat) physicians, their patients, and payers through the development of innovative device technologies and treatments.